LEADER trial: difference between revisions
Diff·revision 16 → 17·23:59, 10 Jun 2025
Difference between revision 16 and revision 17 of LEADER trial. 5 lines changed; the page grew by 605 bytes.
| Revision 16 — 16:18, 11 May 2025 DMF_Dermot (talk) rm the cross-trial comparison; the populations are not comparable 3,566 bytes +29 | Revision 17 — 23:59, 10 Jun 2025 ManualOfStyleMo (talk) expand §Place in the evidence 4,171 bytes +605 | ||
|---|---|---|---|
| 33 | Glycated haemoglobin was about 0.4 percentage points lower on liraglutide, and weight about 2.3 kg lower. Both differences are modest and are part of why the mechanism of the cardiovascular benefit is not attributed to glycaemic control alone.{{r|marso2016}} | 33 | Glycated haemoglobin was about 0.4 percentage points lower on liraglutide, and weight about 2.3 kg lower. Both differences are modest and are part of why the mechanism of the cardiovascular benefit is not attributed to glycaemic control alone.{{r|marso2016}} |
| 34 | 34 | ||
| + | 35 | == Place in the evidence == | |
| + | 36 | LEADER established a cardiovascular benefit for one molecule at one dose in one population. Within the same class, the outcome trials of exenatide and lixisenatide were neutral, so the results do not support a class-wide claim; see [[Exenatide]] and [[GLP-1 receptor agonist]].{{r|marso2016}} | |
| + | 37 | ||
| + | 38 | Whether the differences between trials reflect molecule, dose, exposure duration, population risk or trial size is unresolved. The trials were not designed to answer that question and no adequately powered head-to-head cardiovascular comparison within the class exists.{{r|ich_e9}} | |
| + | 39 | ||
| 35 | == References == | 40 | == References == |
| 36 | {{reflist}} | 41 | {{reflist}} |